Vivo Capital, LLC Viridian Therapeutics, Inc.\De Transaction History
Vivo Capital, LLC
- $683 Million
- Q3 2024
A detailed history of Vivo Capital, LLC transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Vivo Capital, LLC holds 1,678,207 shares of VRDN stock, worth $32.6 Million. This represents 5.59% of its overall portfolio holdings.
Number of Shares
1,678,207
Previous 1,678,207
-0.0%
Holding current value
$32.6 Million
Previous $21.8 Million
74.87%
% of portfolio
5.59%
Previous 3.23%
Shares
3 transactions
Others Institutions Holding VRDN
# of Institutions
178Shares Held
76.6MCall Options Held
581KPut Options Held
439K-
Black Rock Inc. New York, NY4.77MShares$92.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$86 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$75.5 Million9.15% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.75MShares$73 Million3.15% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.45MShares$67 Million12.74% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $776M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...